PTC Therapeutics (PTCT) Q2 FY26 earnings call

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Jul 30, 2026

Source: earnings call transcript

PTC Therapeutics delivered a strong second quarter, driven by the continued robust global launch of Sephience, which saw significant revenue growth and broad market penetration. The company raised its full-year revenue guidance, reflecting confidence in Sephience's trajectory and the unexpected durability of the DMD franchise. Progress in the pipeline, including positive votoplam data and advancement of other clinical programs, further supports the long-term growth outlook, while a strong cash balance provides strategic flexibility.

You’re reading a preview. Opening the full call uses 1 concall credit.

PTCT operating KPIs by quarter

PTCT operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Mar 2026 Q1 FY26	This call Jun 2026 Q2 FY26	Change vs prior quarter
Patients Commercial	1,244 As of March 31, we had 1,244 commercial patients globally. Source: earnings call transcript	1,647 And as of June 30, we had 1,647 commercial patients on Sephience globally. Source: earnings call transcript	+32.4%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.